Pharsight Corp

Pharsight — Investor Presentation (February 2005)

37 slides from Pharsight's investor presentation, Feb 7, 2005

  1. Slide 1: Pharsight Investor Presentation February 2005

    Slide 1: Pharsight Investor Presentation February 2005

    Pharsight Investor February Shawn CynthiaO’Connor Stephens Presentation 2005 Corporation President SVP & CFO & CEO

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking This customer expansion software, remains These development, large Quarterly the Copyright 2 Pharsight date presentation pharmaceutical forward-looking hereof, atdemand, including Report of © the2005 scope changes sole and on contains Statements Pharsight. potential discretion and an

  3. Slide 3: Accelerating clinical drug development for pharmaceutical companies

    Slide 3: Accelerating clinical drug development for pharmaceutical companies

    Deliveringis… Accelerating Improving Copyright 3 Pharsight © client breakthrough 2005 client development Pharsight. product improvement time-to-market All efficiencies rights in reserved. the clinical drug development process to pharmaceutical companies by…

  4. Slide 4: Pharsight Profile

    Slide 4: Pharsight Profile

    Founded Background Profile East Headcount—approx US, OTCBB: Business Market Pharsight® Opportunity WinNonlin® Drug Unique Recent Demonstrable Copyright 4 Pharsight consecutive Europe, Coast Model Financial leading provider 1995; and PHST © Office—Cary, Knowledgebase Australia to Explorer 2005 Produc

  5. Slide 5: Executive Team

    Slide 5: Executive Team

    Executive Shawn President Cynthia Mona Daniel SVP IVAX, William GloboMax, Greg Nancy Russ VP Rene Managing Copyright 5 Pharsight &Software Research Global Consulting & Drug Wada, Lee, Bruno, Lead Sowiski Risch Merrell Weiner, O’Connor Chief Stephens Gillespie, &Team PhD Director, © Development Sales

  6. Slide 6: Our Market Opportunity: Drug Development Productivity Decline

    Slide 6: Our Market Opportunity: Drug Development Productivity Decline

    Our Drug Research High Significant Clinical Long, Of Avg Only Productivity 1 2 Copyright 6 Pharsight 2002 PhRMA 5,000 Market cost 3throughput Development risky out Estimated Development to screened $25 2003 © of Productivity develop and Opportunity: Continues 2005 10 Billion1 Industry complex drugs

  7. Slide 7: Our Market Opportunity: Total Pharma R&D Spend

    Slide 7: Our Market Opportunity: Total Pharma R&D Spend

    Our Market Total $80,000 2003 Phase Branded Development Biotech Generics Copyright 7 Pharsight –Pharma 2004 I 2008 –2.7% $70,000 Pharma 22.6% III ©2005 Opportunity: Estimated CAGR 2005 11.0% Expenditure 2006 8.6% $60,000 Pharsight. 2007 at 34% $50,000 Estimates by 2008 All Segment ofrights Total $40

  8. Slide 8: Our Market Opportunity: Shifting Failure Rates

    Slide 8: Our Market Opportunity: Shifting Failure Rates

    Our Decreasing Chance Today 25 Impact Shifting Improving 1 Copyright 8 Pharsight Pacific Years Market =of of 5% 8% Ago Research Shifting © drug ability FDA Opportunity: of approval 2005 =failures successfully 14% Approval toPharsight. Failure Institute predict approval rate1 from Increasing Rates Ra

  9. Slide 9: Software Products

    Slide 9: Software Products

    Software Products Pharsight

  10. Slide 10: Software Products Overview

    Slide 10: Software Products Overview

    Overview WinNonlin® Industry Pharsight® Enterprise Trial Computer WinNonMix® Population Drug Software-Based Copyright 10 Pharsight Simulator™ Model Standard of Assisted © Data Pharmacokinetic Knowledge Explorer™ Key 2005 (“WNL™”) (“WNM™”) Management Communication Software (“TS2™”) for Pharsight. Cli

  11. Slide 11: WinNonlin

    Slide 11: WinNonlin

    WinNonlin® Industry Key Used Extensive activities One-button Potential Maintain WNL Sales Subscription Copyright 11 Pharsight Software Benefits to Model 5.0simulate Standard Growth market release built-in-library ©export license 2005 (“WNL™”) Offerings share effects announced Drivers for Pharsight.

  12. Slide 12: Pharsight Knowledge Server (PKS)

    Slide 12: Pharsight Knowledge Server (PKS)

    Pharsight® Enterprise Key Data Dramatically Supports Potential Installed Tendency biotech Provide PKS Sales Subscription Copyright 12 Pharsight Software Benefits 3.0 Model upgrade release base Growth compliance to © Data Knowledge follow and 2005 improves of Offerings Management announced current pa

  13. Slide 13: PKS Suite architecture

    Slide 13: PKS Suite architecture

    WinNonlin PKS SAS Excel NONMEM Word Copyright 13 Pharsight Reporter Connectors Clients Knowledgebase © 2005 Pharsight. Suite™ Server All rights “PKS™” reserved.

  14. Slide 14: Trial Simulator

    Slide 14: Trial Simulator

    TrialBenefits State-of-the-Art Key Minimize Intuitive, Formalize Built-in Reduce Growth Increase Sales Subscription Copyright 14 Pharsight Software Simulator™ Model cost Drivers facility potential protocol-based risk assumptions © of license 2005 Offerings of clinical for Clinical trial interoperabi

  15. Slide 15: WinNonMix

    Slide 15: WinNonMix

    WinNonMix® Nonlinear Key Extensive likelihood Growth Increase Provide Sales Subscription Copyright 15 Pharsight Software Benefits Model Drivers upgrade interoperability built-in Mixed or © license 2005 restricted Offerings (“WNM™”) path, Effects library Pharsight. model expanded maximum with (Popula

  16. Slide 16: Drug Model Explorer

    Slide 16: Drug Model Explorer

    DrugBenefits Software-Based Recently Desktop Key Facilitates Powerful, Enables Potential Expand Sales Subscription Copyright 16 Pharsight Software Model client more application Released Growth user-friendly © more Explorer™ and 2005 flexible Offerings base Communication efficient perpetual Drivers P

  17. Slide 17: Software Products Market Acceptance

    Slide 17: Software Products Market Acceptance

    Software Over All early Importance 4 7 14 1 Copyright 17 Pharsight ofPKS Pharma top the adopters 90020 top TM Products customers Exec © Pharma1 of 10 20 customers 2005 DMXTM of Pharma1 50: our Pharsight. Market Pharmaceutical apply (FY2004) new to-date are mentioned DMX our Acceptance PKS All comput

  18. Slide 18: Strategic Consulting Services

    Slide 18: Strategic Consulting Services

    Strategic Consulting Services Pharsight

  19. Slide 19: Strategic Consulting Services Methodology

    Slide 19: Strategic Consulting Services Methodology

    Strategic A Decreases Increases Improves Copyright 19 Pharsight formal,Consulting drug # clinical quantitative, late ©of2005 drugs stage development quality Pharsight. reaching attrition Services model-based andproductivity Decreases All commercial market Methodology rights decision-making perreserv

  20. Slide 20: Strategic Consulting Services Offerings

    Slide 20: Strategic Consulting Services Offerings

    Candidate Preclinical Early Proof-of-concept (I/IIa) Late Go/no-go (IIb/III) Life-cycle Post-Approval Phase Label LEVEL POTENTIAL Scaling Product Support Strategic Copyright 20 Pharsight Phase Phase expansion IIIb/IV (competitors, profile OF in-licensing Consulting consulting decision prioritization

  21. Slide 21: Customer Testimonial: Aventis

    Slide 21: Customer Testimonial: Aventis

    Strategic Aventis simulation, estimates Frank Executive FORBES October Copyright 21 Pharsight Douglas turned 7,Consulting that ASAP VP © 2002 “We 2005 the ofto Aventis stopped Drug aPharsight Pharsight. computer Services Innovation Chief funding computer All model Scientific Customer rights developm

  22. Slide 22: Strategic Consulting Potential Growth Drivers

    Slide 22: Strategic Consulting Potential Growth Drivers

    StrategicFactors Industry Increased Internal Expanding Expanded Continuing Copyright 22 PharsightFactors Consulting acceptance service ©scope recruitment 2005and offering Pharsight. Services of increasing of modeling best All Potential &efficiency rights brightest and simulation reserved. Growth in

  23. Slide 23: Strategic Consulting Market Penetration

    Slide 23: Strategic Consulting Market Penetration

    Strategic 100% 50% Top 30% Existing 1 Copyright 23 Pharsight Pharma 5Market 10 50Pharma Market Pharma Pharsight Consulting Exec © Penetration 2005 Penetration 50:Pharsight. Clients Pharmaceutical Services Unaddressed All Market rights Executive, Penetration reserved. MarketMay Opportunity – Current

  24. Slide 24: Financial Overview

    Slide 24: Financial Overview

    Financial Overview Pharsight

  25. Slide 25: FY04 Accomplishments and FY05 Objectives

    Slide 25: FY04 Accomplishments and FY05 Objectives

    FY04reductions Positive Effected Y-Y Achieved Introduced Fiscal Continued YTD Profitability Expansion Release Additional Announced Copyright 25 Pharsight revenue Y-Y net Accomplishments Year of revenue operating income profitability positive revenue © revenue DMX of new 2004 2005Objectives planned g

  26. Slide 26: Summary Statement of Operations

    Slide 26: Summary Statement of Operations

    Summary (‘000s Q3 FY05 Revenues Cost Gross Operating Income Net common EPS WASO—basic WASO—diluted Copyright 26 Pharsight Q3 income (common), ofFY04 profit except YTD revenues (loss) stockholders $6,462 Statement expenses ©(loss) 4,514 FY05 YTD 2005 per from 19,117 basic diluted 28,195 1,948 $4,583

  27. Slide 27: Summary Results by Segment

    Slide 27: Summary Results by Segment

    Summary Q3 (‘000s) FY05 SOFTWARE STRATEGIC Revenues Gross Income Copyright 27 Pharsight Q3FY04 profit YTD (loss) $4,153 $2,309 Operating ©917 3,597 FY05 YTD 2005 PRODUCTS CONSULTING from 40% 100% 87% Pharsight. FY04 operations Results 924 1,575 $2,284 $2,299 40% $% by All 69% SERVICES 1,397 187 $% 1

  28. Slide 28: Summary Balance Sheet

    Slide 28: Summary Balance Sheet

    Summary Dec (‘000s) Cash ASSETS Accounts LIABILITIES A/P Deferred Notes Redeemable Stockholders Total Copyright 28 Pharsight & 31, Assets & Current Liabilities Payable Payable—Long Accrued 2004 Cash March Revenue—Short Revenue—Long Receivable, Balance © 16,584 Conv 2005 2004 Deficit Equivalents Asse

  29. Slide 29: Equity Structure

    Slide 29: Equity Structure

    Equity (All Common 1.8 Series Automatically Upon At Redemption: Copyright 29 Pharsight election million share close A BStructure 1.8 shares Shares Equivalent data ©Units of of million 2005 at public upon as Conversion: least O/S: =ofPharsight. 1/consent December Shares offering share Series 75% 19.1

  30. Slide 30: Quarterly Revenues by Segment

    Slide 30: Quarterly Revenues by Segment

    Quarterly (‘000s) Software Q1 Copyright 30 Pharsight FY04$7,000 Products Q2 Revenues © 2005 FY04 $6,000 Pharsight. Strategic Q3$5,000 FY04Consulting All Q4 $4,000 rights FY04 $3,000 reserved. Q1 FY05 $2,000 Q2$1,000 FY05 Q3 $0 FY05

  31. Slide 31: Quarterly Gross Profit by Segment

    Slide 31: Quarterly Gross Profit by Segment

    Quarterly (Percentage Strategic Software 90% Q1 Copyright 31 Pharsight FY04 80%Consulting Products Q2 Gross 70% ©of2005 FY04 Segment 60% Profit Pharsight. Q3 50%FY04 Revenues) 40%All Q4 30% rights FY04 20% reserved. Q110% FY05 0%Q2 FY05 Q3 FY05

  32. Slide 32: Sequential Profitability

    Slide 32: Sequential Profitability

    Sequential Profitability (‘000s) Q1 Revenues Copyright 32 Pharsight FY04 Q2Costs © Profitability achieved 2005 FY04 & Pharsight. Expenses Q3Q4 FY04 FY04All Q4$6,500 rights FY04 reserved. $6,000 Q1 FY05$5,500 Q2 FY05 $5,000 Q3$4,500 FY05 $4,000 $3,500

  33. Slide 33: Quarterly Operating Income Growth

    Slide 33: Quarterly Operating Income Growth

    Quarterly (000s) Q1 -$2,000 -$1,500 -$1,000 -$500 Copyright 33 Pharsight FY04 $1,500 Q2 Operating © 2005 FY04 $1,000 Pharsight. Q3 Income $500 FY04 $0Growth All Q4 rights FY04 reserved. Q1 FY05 Q2 FY05 Q3 FY05

  34. Slide 34: Quarterly Operating Cash Flow

    Slide 34: Quarterly Operating Cash Flow

    Quarterly (‘000s) -$500 Q1 Copyright 34 Pharsight FY04 -$1,000 $2,000 Q2 Operating © 2005 FY04 -$1,500 $1,500 Pharsight. Q3 Cash $1,000 FY04 FlowAll Q4 $500rights FY04 $0 reserved. Q1 FY05 Q2 FY05 Q3 FY05

  35. Slide 35: Current Summary

    Slide 35: Current Summary

    Current Summary Increasing and All Copyright 35 Pharsight Support FirstPharma 9© Mindshare Months Our 2005 Market Drive Pharsight. of FY05… for Towards Trends… Quantitative-Based AllSustainable rights reserved. Growth Modeling and&Profitability Simulation… Continuing Pharsight Investment in Revenue

  36. Slide 36: Proprietary Notices

    Slide 36: Proprietary Notices

    Proprietary Notices No Model All Copyright Pharsight 36 part contents other ExplorerTM, ofbrand Corporation. © this Notice Copyright 2005 document andPharsight. product DMXTM, WinNonlin®, ©2005 maynames All be Pharsight Trial rights reproduced are SimulatorTMand WinNonMix® trademarks reserved. Corpo

  37. Slide 37: Pharsight

    Slide 37: Pharsight

    Pharsight.

Source: SEC EDGAR · 8-K filed Feb 7, 2005

More decks from Pharsight Corp